Economic evaluation of betibeglogene autotemcel (Beti-cel) gene addition therapy in transfusion-dependent β-thalassemia
Background Standard of care (SoC) for transfusion-dependent β-thalassemia (TDT) requires lifelong, regular blood transfusions as well as chelation to reduce iron accumulation. Objective This study investigates the cost-effectiveness of betibeglogene autotemcel (‘beti-cel’; LentiGlobin for β-thalasse...
Enregistré dans:
Auteurs principaux: | Anuraag R. Kansal, Odette S. Reifsnider, Sarah B. Brand, Neil Hawkins, Anna Coughlan, Shujun Li, Lael Cragin, Clark Paramore, Andrew C. Dietz, J. Jaime Caro |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Taylor & Francis Group
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/d6cb861054544eae9f3fd0425864a1ec |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
- Thalassemia reports
-
Occult Kidney Dysfunction in Children With Transfusion-Dependent Thalassemia
par: Nurwahida Mohd Zikre, et autres
Publié: (2021) -
Evaluation of Transfusion-Related Hemodynamic Parameters in Patients with Beta-Thalassemia Major by Ambulatory Blood Pressure Monitoring Method
par: Melis Aydın Mut, et autres
Publié: (2021) -
The effect of splenectomy on complement regulatory proteins in erythrocytes in β-thalassemia major
par: Ayşegül Uğur Kurtoğllu, et autres
Publié: (2018) -
Prevalence of abnormal glucose homeostasis in Chinese patients with non-transfusion-dependent thalassemia
par: Luo Y, et autres
Publié: (2019)